Next, the team tested 78 approved or investigational cancer drugs against each of the cell lines, selecting the compounds based on their effectiveness in other solid-tumor cancers. After a series of initial experiments to gauge their effectiveness, 12 of the drugs were prioritized for deeper analysis.

Among these, the research group found six drugs that showed promising results against tumors with particular molecular features suggesting the approach is a solid first step toward developing robust biomarkers of drug response in triple-negative breast cancer.

Many other breast cancer subtypes are defined by the pathways that you would use to target them for example, youd treat HER2-positive breast cancer with a HER-2 inhibitor, says senior study author Sofia Merajver, M.D., Ph.D., a professor of internal medicine and epidemiology at the U-M. Triple-negative breast cancer is defined by its lack of hormone receptors and HER2 expression, which makes it much more difficult to target. We needed to do better.

Since cancer often quickly develops resistances against individual drugs, the researchers also wanted to use their multi-omic approach to look for ideal combinations of drugs.

The idea is that if we find a marker that is particularly high in drug-resistant cells, we might be able to make the cells more responsive to treatment by adding a drug that also targets that marker, says senior study author Matthew Soellner, Ph.D., an assistant professor of internal medicine and chemistry at U-M, and an affiliate faculty member of the U-M Life Sciences Institute. Ultimately, we found we could make most of the cell lines more sensitive to our target drug it worked better than we had hoped for.

The research was supported by the National Institutes of Health (1R21CA218498), the Breast Cancer Research Foundation, Tempting Tables, The Rose Run, and the Kathy Bruk Pearce Research Fund of the U-M Rogel Cancer Center.

Additional authors include Eric J. Lachacz, Nathalie M. Vandecan, Peter J. Ulintz, Liwei Bao, John P. Lloyd, Joel A. Yates and Aki Morikawa, all of U-M.

Paper cited: Molecular determinants of drug response in TNBC cell lines, Breast Cancer Research and Treatment. DOI: 10.1007/s10549-019-05473-9

See the article here:
Approach to Personalizing Treatment of Triple-Negative Breast Cancer Shows Promise in Cell Lines - Michigan Medicine

MEDIA CONTACT

Available for logged-in reporters only

Newswise New Brunswick, N.J., November 11, 2019 Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, has received a $600,000 Translational Award from the V Foundation for Cancer Research to study chronic lymphocytic leukemia (CLL) with the aim of developing research models that may help investigators better understand how CLL cells are influenced by new therapies.

The most common leukemia in the Western world, CLL starts in the bone marrow in a type of white blood cell known as B-lymphocytes. Standard chemotherapy has been successful in treating most patients; however, it is not effective for some patients with specific DNA changes in their leukemia cells. In previous work by Dr. Khiabanian and colleagues, advanced DNA sequencing uncovered mutations that changed the function of a gene called TP53. These mutations could be detected in only a few leukemia cells at initial CLL diagnosis, but would be present in a majority of cells in patients whose CLL returned after treatment with chemotherapy.

To treat such high-risk patients, new drugs have been developed that disrupt processes used by leukemia cells to interact with their environment. One of these drugs, which has shown significant activity in CLL, is ibrutinib. Similar to resistance against chemotherapy, some cells may have alterations that stop this drug from working. As a result, these cells are not killed and can result in the recurrence of CLL. As such, there is a need to better understand these mutations as well as changes in gene expression so that better treatment strategies can be developed. notes Khiabanian, who is part of Rutgers Cancer Institutes Genome Instability and Cancer Genetics Research Program and an assistant professor of pathology and laboratory medicine at Rutgers Robert Wood Johnson Medical School.

He adds, I am grateful for the V Foundation for Cancer Research in its support of this project, which is in line with our labs goal of designing experimental and computational methods that help characterize molecular diversity in small population of cells early in their evolution and transformation.

In this project, the Khiabanian lab will work with the Institute of Oncology Research (Bellinzona, Switzerland) as well as Rutgers Cancer Institute of New Jerseys Hematologic Malignancies Program to analyze patient samples collected during treatment in a clinical trial. Highly sensitive experimental approaches will be applied to thousands of single leukemia cells to develop models that may help describe how CLL cells behave and change under new therapies.

The project period runs through October 2022.

About Rutgers Cancer Institute of New Jersey

As New Jerseys only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy many of which are not widely available patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit http://www.cinj.org/giving.

###

Follow this link:
Examining Molecular Evolution and Impact of Treatment in a Common Form of Leukemia - Newswise

One of the worlds most pre-eminent molecular diagnostics specialists has boosted the board of Cambridge digital health company Congenica.

Dr Heiner Dreismann has accepted roles as non-executive director and senior independent director. He has over 35 years experience in the global leadership of high-growth life sciences and healthcare businesses.

Dr Dreismann was previously president and CEO of Roche Molecular Systems, the world leader in molecular diagnostics, where he made significant contributions to the organisational and financial growth of the companys molecular business area.

Other senior positions he held in Roche included head of global business development, Roche Diagnostics and member of Roches global diagnostic executive committee.

Since leaving Roche he has served on the board of a number of private and public biotech and healthcare companies.

Dr Dreismann said: I am excited to join the board of Congenica, a company at the forefront of healthcare innovation that is bringing medical meaning to genomic data.

I look forward to helping the company in its next stage of growth and in supporting healthcare professionals with its technologies to expedite the diagnosis and treatment of conditions affecting millions of people worldwide.

Congenica enables genomic medicine with what it markets as the worlds leading clinical decision support platform for the interpretation of complex genomic data.

Visit link:
Molecular diagnostics supernova on board at Congenica - Business Weekly

Stacy Jaffee Gropack

Stony Brook, NY, November 13, 2019Stacy Jaffee Gropack, PhD, has been named Dean of the Stony Brook UniversitySchool of Health Technology and Management(SHTM) announced Kenneth Kaushansky, MD, MACP, Senior Vice President of Health Sciences and Dean of the Renaissance School of Medicine at Stony Brook University. With more than 30 years of experience in Health Professions Education, Dr. Jaffee Gropack has previously held the position of Dean of the School of Health Professions at Long Island University (LIU) in Brooklyn, NY.

Dr. Jaffee Gropack has been an innovative leader in moving healthcare professional education to absolute best practices, including interprofessional education, preparing learners not only for the health technology of today but also for what the future will bring, said Dr. Kaushansky.

Dr. Jaffee Gropack received her Bachelor of Science and her Master of Physical Therapy from Long Island University. She then went on to New York University where she received her PhD in Higher Education. Upon returning to LIU, Brooklyn, in the Division of Physical Therapy, her academic career expanded. Dr. Jaffee Gropack became instrumental in developing innovative curricular design at LIU, as well as strategic planning, fostering faculty development and financial management and student performance evaluations. In 2010 she was named Associate Dean of the School of Health Professions at LIU, and then in 2015 was named Dean of the School of Health Professions and Nursing at LIU, Post.

I feel privileged to be able to join Stony Brook University in the capacity of Dean of the School of Health Technology and Management and have the opportunity to lead and collaborate with such a talented group of faculty, administrators and staff in achieving the University and School vision of being the premier educators of future health professionals,she said.

Dr. Jaffee Gropack is the recipient of numerous awards, including a Distinguished Alumnus Award, several awards for teaching excellence, and the Long Island Power Women in Business Award. She has also been active in and served many roles in professional societies, such as the Association of Schools of Allied Health Professions and the American Physical Therapy Association.

Her scholarly work focuses on clinical skills and programs in physical therapy and educational excellence, particularly within interprofessional educational programs and faculty mentoring.

Going forward, Dr. Jaffee Gropack expects to advance the School in areas of scholarship, teaching, service to the community and interprofessional practices, placing a premium on creating a diverse educational and clinical workforce.

The SHTM includes 17 programs offering baccalaureate, masters, and doctoral degreesin clinical and non-clinical areas. Programs include athletic training, health science, physical and occupational therapy, physician assistant studies, clinical laboratory sciences, medical molecular biology, applied health informatics, and respiratory care. The SHTM also offers several advance certificates for workforce advancement. There are over 240 students enrolled in the non-credit certificate programs, over 590 students enrolled in the undergraduate programs, and over 480 students enrolled in the graduate programs.

Dr. Jaffee Gropack emphasizes that the SHTM is dedicated to the education and training of highly competent health care professionals who can assume clinical, advocacy, research, and leadership roles in diverse healthcare settings, with graduates that consistently achieve outstanding pass rates on national board exams.

The school also houses two centers of excellence, The Center for Community Engagement and Leadership Development, and The Center for Public Health Education. The Rehabilitation Research and Movement Performance (RRAMP) Laboratory is central to the promotion of faculty and student research.

###

About Stony Brook UniversityStony Brook University, widely regarded as a SUNY flagship, is going beyond the expectations of what todays public universities can accomplish. Since its founding in 1957, this young university has grown to become one of only four University Center campuses in the State University of New York (SUNY) system with over 26,000 students, more than 2,700 faculty members and 18 NCAA Division I athletic programs. Our faculty have earned numerous prestigious awards, including the Nobel Prize, Pulitzer Prize, Indianapolis Prize for animal conservation, Abel Prize and the inaugural Breakthrough Prize in Mathematics. The University offers students an elite education with an outstanding return on investment: U.S.News & World Report ranks Stony Brook among the top 40 public universities in the nation. Its membership in the Association of American Universities (AAU) places Stony Brook among the top 62 research institutions in North America. As part of the management team of Brookhaven National Laboratory, the University joins a prestigious group of universities that have a role in running federal R&D labs. Stony Brook University fuels Long islands economic growth. Its impact on the Long island economy amounts to $7.38 billion in increased output. Our state, country and world demand ambitious ideas, imaginative solutions and exceptional leadership to forge a better future for all. The students, alumni, researchers and faculty of Stony Brook University are prepared to meet this challenge.

See the rest here:
Innovative Educator and Healthcare Professional Named Dean of the School of Health Technology and Management - Stony Brook News

Perth researchers discover way to enhance immune response and drug treatment of stiff, difficult-to-treat solid cancers

Some solid tumours are so stiff they make a cracking noise when they are cut by researchers on the laboratory bench.

The fibrous nature of liver, pancreatic and some breast cancers make them difficult to treat. However, five years of research by a team of Perth scientists has resulted in the development of a novel, non-toxic agent that can deliver drugs to the cancer cells embedded in the fibrous matrix.

Research published in EMBO Molecular Medicine showed a non-toxic therapeutic agent boosted immune cells to selectively remove the fibrous scar tissue allowing cancer treatments to reach their target.

Dr Juliana Hamzah, head of the Targeted Drug Delivery, Imaging and Therapy Laboratory at the Harry Perkins Institute of Medical Research said by breaking down the fibrous matrix of stiff tumours the patients own immune system paved the way for drug treatments to take effect.

The cancer is like a wound, and a way that our body tries to repair the wound is to grow a scar tissue around it, but that scar tissue makes it very difficult to get to the cancer cells to destroy them.

It is stiff, non-cellular, has very few blood vessels and impenetrable. The scar tissue is not only a physical barrier but it constricts blood vessels which are key pathways for delivering cancer treatment.

The barrier around some cancers, such as liver cancer, pancreatic cancer and some breast cancers is like barbed wire.

We have developed a non-toxic agent that does not affect surrounding healthy tissue.

The agent activates immune cells to release enzymes that digest the scar tissue. This allows more cancer killing immune cells to enter the tumour. Our results show that removal of the fibrous tissue dramatically eliminates the drug delivery barrier.

Tumours treated with the drug weve developed are more permeable to anti-tumour immune cells and cancer treatments, Dr Hamzah said.

The research data have been validated in four laboratories including the Harry Perkins Institute of Medical Research in Perth, the School of Engineering at The University of Western Australia, Sanford Burnham Prebys Medical Discovery Institute, California, USA, and the University California Davis, California, USA.

Dr Hamzah says that now the drug has been proven to have a positive impact on fibrosis, or scar tissue, she is investigating whether it can be used to prevent malignant cancer by treating the early stages of fibrosis in liver cancer.

If you take liver cancer, it doesnt start immediately as cancer, it starts as fibrosis, cirrhosis, which then develops into liver cancer.

Because chronic tissue fibrosis can lead to cancer we aim to investigate whether early treatment with our drug of the pre-cancerous stage, such as liver fibrosis, could prevent development of malignant cancer.

Continued here:
Press Release: New drug that breaks down the 'barbed wire' around some cancers - PRWire

This Global Fluoroscopy & C Arms Market byData Bridge Market Researchbrings all the figures needed to corner the Global fluoroscopy and C-arms market by showing all the recent developments, product launches, joint ventures, mergers and accusations done by the key players and brands that are making a mark in the market. Besides it also pinpoints the market drivers and restraints with the help of SWOT analysis.

Global fluoroscopy and C Arms marketis expected to reach at a CAGR of 4.3% in the forecast period of 2018 to 2025.

The main perspective of the Fluoroscopy and Mobile C-Arms report is to support companies comprehend the customer in terms of approach, cultural trends, routine factors and how social framework impacts product selection and usage. It evaluates the quality of service that has been provided to the customer or to provide information about various operational aspects. The Fluoroscopy and Mobile C-Arms report serves with all inclusive, highly effective and thoroughly analyzed information in a well-organized manner, based on actual facts, the information of the market trends is mentioned in the report. The Fluoroscopy and Mobile C-Arms report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

Get Sample copy of this Report @https://databridgemarketresearch.com/request-a-sample/?dbmr=global-fluoroscopy-c-arms-market

Some of the prominent participants operating in this market are GE Healthcare, Koninklijke Philips N.V., Siemens AG, Canon Medical Systems Corporation, Shimadzu Corporation, Carestream Health, EcoRay, Eurocolumbus s.r.l., GEMSS Co., Ltd., Hitachi, Ltd., Hologic Inc., INTERMEDICAL S.r.l., ITALYRAY, PAUSCH Medical GmbH, Varex Imaging Corporation, Whale Imaging, and Ziehm Imaging GmbH among others.

Study Highlights

Request ForTOC@https://databridgemarketresearch.com/toc/?dbmr=global-fluoroscopy-c-arms-market

GE Healthcare founded in 1918, headquarters in New York, U.S., and focuses towards the manufacturing and developer of medical imaging, digital solutions, patient monitoring and diagnostics, drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions.

Access Full Report:https://databridgemarketresearch.com/reports/global-fluoroscopy-c-arms-market/

The company has its presence in U.S, Europe, Asia, Americas, Middle East and Africa.

Koninklijke Philips N.V.:

Koninklijke Philips N.V., founded in 1891 and based in Amsterdam, Netherlands. The company focuses on improving peoples health and enabling better outcomes across the health continuum from healthy living and prevention to diagnosis, treatment and home care.

The company has its presence in Netherland, United states, China, Germany, Japan, France, India and Others.

Siemens AG:

Siemens AG, founded in 1896 and based in Munich, Germany. The company provides manufacturing, distributing and services of medical devices and pharma Services. Company is engaged in providing precision medicines, transforming care delivery, innovative technology in area of diagnostics, molecular medicine and many others. The company has its presence in Europe, C.I.S., Africa, Middle East, Americas , Asia, Australia.

Market Developments:

Inquiry Before Buying AThttps://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-fluoroscopy-c-arms-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:sopan.gedam@databridgemarketresearch.com

Read more:
Fluoroscopy and Mobile C-Arms Market to reach USD 3,051.4 million by 2026 | Technology Development Trends, Business Growth Opportunities, Competitive...